
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is supported by a strong late-stage CRO demand backdrop, with record 3Q net new business awards of $873 million, LTM awards up 23.9% year over year, and management expecting gross and net bookings to keep improving. The company’s win rates and RFP activity are strengthening, aided by more normalized pricing, faster customer decision timelines, and improving biotech funding, while cancellations remain within the normal 3-5% range and are driven more by product failures and reprioritization than funding pressure. Consensus still implies about 5% revenue growth and 4.5% EBITDA growth, and the $20 million Cincinnati expansion cost should later support operating leverage as the facility ramps.
Bears say
Medpace Holdings is exposed to a cyclical and policy-sensitive CRO market where government reform, macro weakness, and biotech funding constraints can reduce demand for outsourced trials and trigger elevated cancellations, particularly among smaller, pre-revenue customers. Although its $28 billion addressable market and high exposure to emerging biopharma have supported outsized growth versus peers, that same mix raises volatility, and the company’s recent improvement in bookings does not eliminate risk. Management’s rising customer concentration, with the top 5 customer revenue share estimated at 33% in 2Q and tied to a small number of large metabolic programs, creates a meaningful revenue overhang if those trials roll off.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Medpace Holdings (MEDP) Forecast
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares